 Introduction
Phenylketonuria (PKU) is an inherited metabolic disease characterized by phenylalanine (Phe) accumulation, in which the enzyme phenylalanine hydroxylase (PAH) does not function properly, which helps the body to break down Phe. This genetic disease can lead to neurocognitive and neuromotor impairment as mental retardation, behavioral abnormalities, seizures, an inability to focus and organize information, and other neurologic complications.
PKU is an orphan disease with incidence rate 1:5000 in Egypt. Sapropterin dihydrochloride, an FDAapproved synthetic formulation of tetrahydrobiopterin (6R-BH4, herein referred to as sapropterin) is effective in reducing plasma Phe concentrations in patients with hyperphenylalaninemia due to tetrahydrobiopterin (BH4)-responsive PKU, offering potential for improved metabolic control [1] .
 Objective
Phenylketonuria (PKU) is an orphan disease with incidence rate 1:5000 in Egypt. Cost-effectiveness of Sapropterin versus Phenylalanine (PHE) free diet in PKU patients from the insurer perspective was evaluated over a time horizon of 10 years. 
Target population
Those who are insured by the Egyptian health care system.
Subgroup analysis
Only for those whom clinical and cost effectiveness may be expected to differ from that of the overall population.
Choice of comparator
Phenylalanine (PHE) free diet Time horizon over a ten-year period Assumptions required yes
Analytical technique
Cost-utility analysis
Costs to be included
Total costs include costs of treatment and managing complications according to the Egyptian current practice.
Source of costs
Official sources of unit cost data for products (e.g.
Tender lists) Modeling
Markov model Systematic review of evidences yes Preference for effectiveness over efficacy yes
Outcome measure
The outcomes of the two treatments were measured in terms of quality-adjusted life-years (QALYs)
Method to derive utility
The direct use of EQ-5D
Equity issues stated
All lives, life years, or QALYs are valued equally, regardless of age, gender, or socioeconomic status of individuals in the population
Discounting costs
A discount rate of 3.5 % per year is used for costs.
Discounting outcomes
A discount rate of 3.5 % per year is used for outcomes.
Sensitivity analysis-parameters and range
Critical component(s) in the calculation is varied through a relevant range or from worst case to best case.
Sensitivity analysis-methods
One-way sensitivity analysis is performed.
Presenting results
Sapropterin doesn't represent a good value for money compared to PHE free diet in the Egyptian PKU patients Incremental analysis yes Total costs vs. effectiveness (cost/effectiveness ratio) yes
Portability of results (Generalizability)
The generalizability and extent to which the clinical efficacy data and the economic data are representative is identified and discussed. It is important to identify the most cost-effective treatment in women with postmenopausal osteoporosis from a range of alternatives. To support reimbursement decision-making in Egypt, Decision analysis is a quantitative method for synthesizing data from numerous sources for the evaluation of treatment alternatives and was developed to determine the cost-effectiveness of the Sapropterin as compared to, the currently used regimen, Phenylalanine Free Diet.
Initiating Sapropterin is likely to improve the management of patients with PKU. Our results demonstrate that Sapropterin versus Phe free diet is not cost effective for patients with mild and classical PKU. Interestingly, Sapropterin group showed small incremental effects when compared with Phe free diet. At the same time, costs associated with Sapropterin group are higher than costs associated with Phe free diet group.
The strength of our model is the use of relative risk data from a 22-week, multicenter, open-label randomized placebo-controlled study on eighty patients [1] . In addition, incorporating quality of life issues may be important in clinical decisions. The epidemiologic parameters part of our analysis was supported by publications conducted in Egypt [2, 3] . As well as the decision analysis approach on Sapropterin are lacking, this study is the first to incorporate a decision analysis approach comparing the cost-effectiveness of Sapropterin versus Phe free diet in patients with PKU.
In our analysis, we explicitly took model inputs uncertainty into account by assigning plausible ranges to quality of life, relative risk and epidemiologic parameters in the model. This allowed us to perform one way sensitivity analysis that showed no impact on the results. To assess the influence of other model structures and assumptions on the cost-effectiveness estimate we performed one-way sensitivity analyses on various parameters. Various sensitivity analyses did not result in qualitative changes of our results, and the model proved to be rather robust. In a situation where a decision has to be taken, the only rational way for a risk-neutral decision-maker is not to adopt Sapropterin strategy unless there is a cut in Sapropterin price.
There are some limitations that need to be considered when assessing its relative generalizability. First, the additional costs of sapropterin are difficult to estimate due to variations in weights of children so the perspective was that of an insurer perspective and not a societal one and as such we excluded indirect costs or out-of-pocket direct costs incurred by the parent of the patient. Second, our analysis was mainly based on effectiveness data from one RCT comparing Sapropterin versus Phe free diet in patients with PKU.
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Tel.: +202 -23684288 +202 -23648769 +202 -25354100 On the basis of the available evidence, our results are likely to be similar to the National Centre for Pharmacoeconomics (NCPE) in Ireland who didn't recommend sapropterin as an add-on treatment for patients with PKU as well as the Pharmaceutical Benefits Advisory Committee (PBAS) in Australia and National health service (NHS) in Britain rejected the submission for sapropterin because of uncertainty around the clinical place in therapy and high and uncertain cost effectiveness. Current dietary management with a phenylalanine-free diet remains the intervention of choice [4, 5, 6] . The main driver of the absence of a demonstration of Sapropterin costeffectiveness from this model is that the Cost per QALY data is unavailable due to the paucity of quality of life data in the literature and the high price of Sapropterin Tablets.
As in all modeling exercises, several assumptions were made in this study leading to uncertainties in the results. In this analysis, we explicitly accounted for these uncertainties by assigning confidence intervals and plausibility ranges based on published sources to the quality-of-life, and costs in the model. To assess the influences of other model structures and assumptions on the cost-effectiveness estimates, one-way sensitivity analyses of various parameters were performed. These various sensitivity analyses did not result in qualitatively different results, and the model proved to be rather robust.
 Conclusion
It is important to address both the clinical and the economic implications of a new therapy from the payer perspective before deciding on public reimbursement of new therapies. World Health Organization recommends that interventions that cost more than 3 times GDP/capita for one Disability Adjusted Life Year (DALY) avoided should not be reimbursed. Despite the difference between DALY and QALY, one can assume they are similar to be able to put a value on the outcome. This means that, compared with alternative uses of scarce health care resources, Sapropterin doesn't represent a good value for money compared to PHE free diet in the Egyptian PKU patients. Whether Sapropterin is cost-effective in certain subgroups needs to be addressed in future studies.
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